Market Overview
Noninvasive Cancer Diagnostics Market size was valued at USD 151,587.50 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 9.40% over the forecast period 2023- 2030. Noninvasive diagnostics is a method for the detection of disease through minimum incisions into the body. Noninvasive cancer diagnostic technologies give fast and convenient early noninvasive cancer detection procedures, provide valuable aid to the clinician, and increase comfort. These technologies reduce the mortality rate by providing treatment in the early stage of the disease. Noninvasive cancer diagnostics is gaining importance over conventional diagnosis due to increased incidences of chronic cancer such as breast cancer and lung cancer.

Market Dynamics
The non-invasive cancer diagnostics market growth is driven by the increasing prevalence of various types of cancer and the growth of the ageing population are the major factors driving the growth of the noninvasive cancer diagnostic market.
An increase in incidences of chronic cancer such as breast cancer and lung cancer will drive the market growth
Non-invasive cancer diagnostics is growing in importance over conventional diagnosis techniques due to increased incidences of chronic cancer such as breast cancer and lung cancer. According to the American Cancer Society, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States in 2020.
Lung cancer still caused more deaths in 2017 than breast, prostate, brain colorectal cancers joined. The mortality drops were also dramatic for melanoma of the skin in the viewing of US Food and Drug Administration approval of novel therapies for metastatic disorder, escalating to 7% annually during 2013 into 2017 from 1% during 2006 by 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in people aged 65 years and older are especially striking because rates in this age group were rising before 2013. It is also renowned that long-term rapid increases in liver cancer death have attenuated women and sustained men. In summary, slowing momentum for some cancers responsive to early detection is compared with notable gains for other common cancers.
Therefore advanced and reliable detection of cancer along with monitoring its growth at later platforms is very critical. Though invasive cancer diagnoses are correct in the early stages, the same procedures cannot be used to monitor cancer tumors at different stages since surgeries are needed for these types of diagnoses. The non-invasive cancer diagnosis market has growth potential all across the world.
The growth of the ageing population is the primary factor driving the growth of the noninvasive cancer diagnostic market
As cancer is more prevalent in the elderly population, the rising ageing population is also expected to propel market growth. For instance, Global Health and Aging report published by the World Health Organization, the number of people aged 65 years or greater is expected to increase from a predicted 524 million in 2010 to about 1.5 billion by 2050, with a significant percentage of increase in emerging economies. Primary chronic diseases such as cancer have had the most significant impact on the geriatric population, especially in high-income countries.
Detection of cancer at an initial stage significantly raises the possibilities for survival. Creating awareness to promote early diagnosis and screening are the essential steps responsible for early detection of disease comprising breast, blood, colorectal, lung, and cervical, among others. Recognizing likely warning symptoms of cancer and taking active measures is necessary for early diagnosis.
Thus, given the aforementioned factors, the noninvasive cancer diagnostics market is expected to witness tremendous growth over the forecast period.
The high expense of diagnostic procedures will hamper the market growth
However, the high expense of diagnostic procedures and stringent regulatory requirements hinder the growth of the global noninvasive cancer diagnostics market.

COVID-19 Impact Analysis
According to the CDC, the senior population with underlying severe therapeutic conditions, including people with cancer, might be at higher risk for severe illness from COVID-19. Patients with cancer are at higher risk for severe COVID-19.
According to a research article by Hidenori Toyoda et al., published in Hepatology Communications Journal 2020, during the COVID?19 pandemic 2020, strict measures were implemented by the government to prevent the spread of COVID-19, which adversely affected the routine monitoring of cancer. Therefore, these patients were considered in the emergency category during the pandemic. Besides, the increased sales of cancer products will foster healthy growth of the market amid COVID-19.

Segment Analysis
By therapeutics, the noninvasive cancer diagnostics market is classified into solid tumours, blood cancer, lung cancer, breast cancer, others.
The blood cancer segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
As per the Bristol-Myers Squibb Company report, above 1.85 million new blood cancer cases are anticipated to be diagnosed across the globe in 2040, in which 918,872 cases are from lymphoma, 275,047 cases myeloma and 656,345 from leukemia. Furthermore, the report predicted, in 2040, the estimated number of deaths worldwide due to blood cancer will be 1,100,000. In 2019, higher than 387,000 people lived with leukemia in the U.S., and an expected 68,000 deaths will result from blood cancer. As per the national cancer institute, the expected deaths due to blood cancer are about 22,840 in 2019. The escalating deaths and rising incidence of blood cancer cases globally drive the market.
Based on therapy, the Noninvasive Cancer Diagnostics Market is classified into targeted therapy, radiation therapy, immunotherapy, chemotherapy.
Based on techniques, the noninvasive cancer diagnostics market is classified into clinical chemistry, immunochemistry/immunoassay, molecular diagnostics, other clinical instruments.
The molecular diagnostics segment are expected to dominate the noninvasive cancer diagnostics market during the forecast period
Molecular diagnostics recognize the presence of cancer cells by examining their biological molecules. Several tests are conducted on the blood, tumor tissue and saliva, samples for detecting and measuring particular genetic sequences in the RNA, DNA and cell proteins. Molecular diagnostics help perform rapid analysis and provide accurate information that is further used in the personalized diagnosis of cancer. These diagnostics solutions find application in clinical and point-of-care (POC) examinations to detect cancer. They are also utilized in blood banks to identify infectious diseases and pathogens present in the donated blood samples.

Geographical Analysis
North America region holds the largest market share in the global noninvasive cancer diagnostics market
North America region is dominating the global noninvasive cancer diagnostics market accounted for the largest market share in 2020, owing to the growing incidence of cancer cases in the country, the presence of key market players, and the launch of new commodities influence market growth in the region.
As per the American Society of Clinical Oncology 2019 report, an expected 228,150 adults in the United States were expected to be diagnosed with lung cancer. Lung cancer causes up about 13% of all new cancer treatments. Lung cancer is the second common cancer and the foremost cause of cancer death for adults in the US. The report predicted that 142,670 deaths from this disease would occur in the year 2019.
However, North American countries such as the United States and Canada have an advanced and well-structured health care system. These systems also support research and development. These policies support global players to penetrate the US and Canada markets. As a result, these nations enjoy the presence of many market players. As global players in the region meet the high requirement, the market is further expected to increase in the forecast period.
On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period due to the increase in healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and effective treatment in emerging countries, such as China and India.

Competitive Landscape
The non-invasive cancer diagnostics market is moderately competitive with the presence of local as well as global companies. Some of the key players contributing to the growth of the market include Roche, Precision Therapeutics, Affymetrix Inc., Gen-Probe Incorporated, AVIVA Biosciences Corporation, A&G Pharmaceutical, BIOVIEW Inc., Quest Diagnostics Incorporated, Digene Corporation, and Laboratory Corporation of America Holdings. Among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the noninvasive cancer diagnostics market globally.
Roche Diagnostics
Overview: Roche Diagnostics is a diagnostic department of Hoffmann-La Roche, producing equipment and reagents for research and medical diagnostic applications. Applied Science targets research contexts in academia and biotechnology, and pharmaceutical industries. Internally, it is classified into five major business areas: Roche Applied Science, Roche Tissue Diagnostics (Ventana), Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics. The primary location for Roche Professional Diagnostics is in Rotkreuz, Switzerland.
Product Portfolio: The Company’s portfolio comprises centralized and point of care solutions, custom biotech, diabetes care, molecular diagnostics & research, among others.